The Bioinformatics Analysis of miRNAs Signatures Differentially Expressed in HER2(+) Versus HER2(-) Breast Cancers

被引:3
|
作者
Nie, Weiwei [1 ]
Jin, Lei [2 ]
Wang, Yanru [1 ]
Wang, Zexing [3 ]
Guan, Xiaoxiang [1 ,3 ]
机构
[1] So Med Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[2] Nanjing Univ, Jinling Hosp, Sch Med, Dept Stomatol, Nanjing 210002, Jiangsu, Peoples R China
[3] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing 210002, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
bioinformatics; breast cancer; HER2; miRNAs; MICRORNAS;
D O I
10.1089/cbr.2012.1311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To identify the signatures of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers that accurately predict the HER2 status of breast cancer, and to provide further insight into breast cancer therapy. Methods: By the methods of literature search, aberrant expressed miRNAs were collected. By target prediction algorithm of TargetScan and PicTar and the data enrichment analysis, target gene sets of miRNAs differentially expressed in HER2(+) versus HER2(-) breast cancers were built. Then, using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) database, the function modules of Gene Ontology categories and Kyoto Encyclopedia of Genes and Genomes (KEGG) and BIOCARTA pathway, biological functions and signaling pathways that are probably regulated by miRNAs, were analyzed. Results: We got five sets of miRNAs expressed in different HER2 status of breast cancers finally. The five sets of data contain 22; 32; 3; 38; and 62 miRNAs, respectively. After miRNAs target prediction and data enrichment, 5,734; 22,409; 1,142; 22,293; and 43,460 target genes of five miRNA sets were collected. Gene ontology analysis found these genes may be involved in transcription, protein transport, angiogenesis, and apoptosis. Moreover, certain KEGG and BIOCARTA signaling pathways related toHER2 status were found. Conclusion: Using TargetScan and PicTar for data enrichment, and DAVID database, Gene Ontology categories, KEGG and BIOCARTA pathway for analysis of miRNAs different expression, we conducted a new method for biological interpretation of miRNA profiling data in HER2(+) versus HER2(-) breast cancers. It may improve understanding the regulatory roles of miRNAs in different molecular subtypes of breast cancers. Therefore, it is beneficial to improve the accuracy of experimental efforts to breast cancer and potential therapeutic targets.
引用
收藏
页码:71 / 76
页数:6
相关论文
共 50 条
  • [1] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Horimoto, Yoshiya
    Ishizuka, Yumiko
    Ueki, Yuko
    Higuchi, Toru
    Arakawa, Atsushi
    Saito, Mitsue
    BMC CANCER, 2022, 22 (01)
  • [2] HER2 status and disparities in luminal breast cancers
    Holowatyj, Andreana N.
    Ruterbusch, Julie J.
    Ratnam, Manohar
    Gorski, David H.
    Cote, Michele L.
    CANCER MEDICINE, 2016, 5 (08): : 2109 - 2116
  • [3] Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
    Yoshiya Horimoto
    Yumiko Ishizuka
    Yuko Ueki
    Toru Higuchi
    Atsushi Arakawa
    Mitsue Saito
    BMC Cancer, 22
  • [4] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [5] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
    Jensen, Steffen Grann
    Thomas, Peter Engel
    Christensen, Ib Jarle
    Balslev, Eva
    Hansen, Alastair
    Hogdall, Estrid
    APMIS, 2020, 128 (11) : 573 - 582
  • [6] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Yao-Shan Fan
    Carmen E. Casas
    Jinghong Peng
    Melanie Watkins
    Lynn Fan
    Jennifer Chapman
    Offiong Francis Ikpatt
    Carmen Gomez
    Wei Zhao
    Isildinha M. Reis
    Breast Cancer Research and Treatment, 2016, 155 : 457 - 462
  • [7] HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline
    Fan, Yao-Shan
    Casas, Carmen E.
    Peng, Jinghong
    Watkins, Melanie
    Fan, Lynn
    Chapman, Jennifer
    Ikpatt, Offiong Francis
    Gomez, Carmen
    Zhao, Wei
    Reis, Isildinha M.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 155 (03) : 457 - 462
  • [8] In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer
    Melanie Spears
    Karen J. Taylor
    Alison F. Munro
    Carrie A. Cunningham
    Elizabeth A. Mallon
    Chris J. Twelves
    David A. Cameron
    Jeremy Thomas
    John M. S. Bartlett
    Breast Cancer Research and Treatment, 2012, 132 : 463 - 470
  • [9] Is HER2 ultra-low breast cancer different from HER2 null or HER2 low breast cancer? A study of 1363 patients
    Chen, Zhaoxu
    Jia, Huiqing
    Zhang, Huina
    Chen, Lifang
    Zhao, Peng
    Zhao, Jing
    Fu, Guangming
    Xing, Xiaoming
    Li, Yujun
    Wang, Chengqin
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 202 (02) : 313 - 323
  • [10] HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers
    Li, Bob T.
    Ross, Dara S.
    Aisner, Dara L.
    Chaft, Jamie E.
    Hsu, Meier
    Kako, Severine L.
    Kris, Mark G.
    Varella-Garcia, Marileila
    Arcila, Maria E.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) : 414 - 419